EP2023923A2 - Verwendung von ixabepilon in kombination mit cyp3a4-hemmern für arzneimittel - Google Patents

Verwendung von ixabepilon in kombination mit cyp3a4-hemmern für arzneimittel

Info

Publication number
EP2023923A2
EP2023923A2 EP07784137A EP07784137A EP2023923A2 EP 2023923 A2 EP2023923 A2 EP 2023923A2 EP 07784137 A EP07784137 A EP 07784137A EP 07784137 A EP07784137 A EP 07784137A EP 2023923 A2 EP2023923 A2 EP 2023923A2
Authority
EP
European Patent Office
Prior art keywords
ixabepilone
cancer
ketoconazole
cyp3a4
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07784137A
Other languages
English (en)
French (fr)
Inventor
Marvin Barry Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP2023923A2 publication Critical patent/EP2023923A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07784137A 2006-05-25 2007-05-25 Verwendung von ixabepilon in kombination mit cyp3a4-hemmern für arzneimittel Withdrawn EP2023923A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80319306P 2006-05-25 2006-05-25
PCT/US2007/069741 WO2007140299A2 (en) 2006-05-25 2007-05-25 Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals

Publications (1)

Publication Number Publication Date
EP2023923A2 true EP2023923A2 (de) 2009-02-18

Family

ID=38779372

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07784137A Withdrawn EP2023923A2 (de) 2006-05-25 2007-05-25 Verwendung von ixabepilon in kombination mit cyp3a4-hemmern für arzneimittel

Country Status (2)

Country Link
EP (1) EP2023923A2 (de)
WO (1) WO2007140299A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2009114A1 (de) * 2007-06-29 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Verfahren, Kits und Verbindungen zur Bestimmung der Ansprechempfindlichkeit auf eine Behandlung einer pathologischen Störung mittels Epothilonen
US8501792B2 (en) 2008-02-19 2013-08-06 David A. Potter Treating cancer with desthiazolyl ritonavir
HUE027831T2 (en) * 2010-03-12 2016-11-28 Genzyme Corp Combination therapy for breast cancer
US20220143011A1 (en) 2017-05-16 2022-05-12 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
CA3062770A1 (en) * 2017-05-16 2018-11-22 Bow River LLC Use of a cyp3a4 substrate drug with a cyp3a4 substrate inhibitor
US10835529B2 (en) 2017-05-16 2020-11-17 Bow River LLC Methods of treatment with CYP3A4 substrate drugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003201D0 (en) * 2000-02-11 2000-04-05 Pharmacia & Upjohn Spa Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
AU2002236765A1 (en) * 2001-01-16 2002-07-30 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
EP1353667A1 (de) * 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenterale zusammensetzungen enthaltend epothilon-analoge
AU2003243561A1 (en) * 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICAL TRIALS: "View of NCT00096317 on 2005_06_23", 23 June 2005 (2005-06-23), Retrieved from the Internet <URL:http://clinicaltrials.gov/archive/NCT00096317/2005_06_23> [retrieved on 20110420] *

Also Published As

Publication number Publication date
WO2007140299A2 (en) 2007-12-06
WO2007140299A3 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
EP1383490B1 (de) Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
EP2127652B1 (de) Verfahren zur behandlung von krebs mit antikrebsmittel in einer kombinatonstherapie
USRE41393E1 (en) Treatment of refractory tumors using epothilone derivatives
US20070009593A1 (en) Methods of treating cancer
WO2007140299A2 (en) Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals
AU2002248542A1 (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
EP3432886B1 (de) Pim-kinase-hemmer in kombination mit rna-spleissungsmodulatoren/inhibitoren zur behandlung von krebs
JP2004522771A (ja) 治療抵抗性腫瘍の処置用エポチロン誘導体
WO2004103267A2 (en) Methods to administer epothilone d
CZ2004287A3 (cs) Prostředky a způsoby pro léčení rakoviny
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
EP2030618A2 (de) Kombinationen enthaltend Epothilone und Antimetaboliten
US11389440B2 (en) PIM kinase inhibitors in combination with autophagy inhibitors for treatment of cancers
JP2022547702A (ja) 胆管癌の処置のためのパノビノスタットを含む併用療法
US20220071982A1 (en) Methods and uses for treating cancer
AU2004251444B2 (en) Cancer treatment with epothilones
AU2014264318B2 (en) Combination of a PI3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck
Mani et al. Ixabepilone
Egerton Ixabepilone Treatment Schedules in Advanced Breast Cancer
JP2005520820A (ja) （ａ）ｃ−ａｂｌキナーゼ活性のＡＴＰ−競合阻害剤と（ｂ）２種またはそれ以上の他の抗腫瘍薬の組合わせ

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081205

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20090324

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110910